KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Palvella Therapeutics (PVLA) EBIAT (2016 - 2026)

Palvella Therapeutics has reported EBIAT over the past 10 years, most recently at -$9.7 million for Q3 2022.

  • Quarterly EBIAT rose 41.34% to -$9.7 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was -$34.7 million through Sep 2022, up 31.51% year-over-year, with the annual reading at -$41.7 million for FY2025, 139.27% down from the prior year.
  • EBIAT was -$9.7 million for Q3 2022 at Palvella Therapeutics, up from -$10.3 million in the prior quarter.
  • Over five years, EBIAT peaked at -$203000.0 in Q2 2018 and troughed at -$16.5 million in Q3 2021.
  • The 5-year median for EBIAT is -$9.5 million (2021), against an average of -$8.4 million.
  • Year-over-year, EBIAT soared 97.99% in 2018 and then tumbled 5692.12% in 2019.
  • A 5-year view of EBIAT shows it stood at -$11.7 million in 2018, then skyrocketed by 93.13% to -$802000.0 in 2019, then plummeted by 1695.51% to -$14.4 million in 2020, then soared by 33.76% to -$9.5 million in 2021, then decreased by 1.7% to -$9.7 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's EBIAT are -$9.7 million (Q3 2022), -$10.3 million (Q2 2022), and -$5.1 million (Q1 2022).